EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 673 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Working Together to Choose a Cancer Treatment Plan: A Caregiver’s Perspective June 16, 2022 ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival June 29, 2021 Cancer Rehabilitation Starts at Diagnosis: Part II July 13, 2021 Load more HOT NEWS “That is what I dream”: India’s journey to rolling out the... Why haven’t we cured cancer? How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described
